Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
Yanxing Cai(Fudan University), Shibo Jiang(Shanghai Medical College of Fudan University), Youhua Xie(Shanghai Medical College of Fudan University), Chenjian Gu(Washington University in St. Louis), Xia Cai(Fudan University), Wei Xu(Beijing Geriatric Hospital), Di Qu(Xijing Hospital), Lu Lu(Shanghai Medical College of Fudan University)
Cited by 61
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400